Atea Pharmaceuticals, Inc. (AVIR) Return on equity 2021–2022
Atea Pharmaceuticals, Inc. (AVIR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-16.3%FY2022 · since FY2021: 22.1% → -16.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -16.3% | -38.4 pp |
| FY2021 | 22.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice